In this phase III, multicenter study, 1200 patients with lung, breast, gastrointestinal
(stomach, colon-rectum, pancreas), ovarian or head and neck cancer undergoing chemotherapy
will be randomly assigned (at the beginning of cytotoxic therapy) in a 2:1 ratio and in
double-blind conditions to a treatment with subcutaneous low molecular weight heparin
(nadroparin calcium, one injection/day) or placebo for the overall duration of chemotherapy
or up to a ... Read More
The trial will test the effectiveness and toxicity of subcutaneous treatment with one cycle
of cladribine in patients with hairy cell leukemia requiring treatment.
They have to be untreated so far or may be pretreated with alpha-interferon.
The study will test the effectiveness (rate of complete remissions, total remission rate and
duration of remission) and toxicity of the combined immuno/chemotherapy with subcutaneous
cladribine (LITAK®) plus anti-CD20* antibody rituximab in patients requiring treatment for
relapsed hairy cell leukaemia or hairy cell leukaemia variant independent of any previous
CD20* = cluster of differentiation antigen 20
The purpose of the Connect® MM Registry is to explore the natural history and real world
management of patients with newly diagnosed symptomatic multiple myeloma (MM) and provide
unique insights into the management of MM and the impact of this hematologic disorder on
This is a randomized, open label, multicenter clinical trial to compare the efficacy and
safety of Velcade (bortezomib) and dexamethasone versus Velcade, thalidomide, and
dexamethasone versus Velcade, melphalan, and prednisone in patients with previously
untreated multiple myeloma not considered candidates for high-dose chemotherapy and
autologous stem cell transplantation.
The purpose of this research study is to determine if TLK286 given in combination with
carboplatin is more effective than liposomal doxorubicin in treating women who have
recurrent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer,
that is refractory or resistant to platinum chemotherapy.
The purpose of this study is to determine the safety and effectiveness of combination
therapy with Proleukin and Rituxan on patients with low-grade Non-Hodgkin's Lymphoma who
have previously failed Rituxan treatments.
The purpose of this study is to demonstrate superiority in survival in favor of TLK286 as
compared to active control therapy with Doxil/Caelyx or Hycamtin in the intent-to-treat
The investigators hypothesize that the combination of eflornithine and sulindac will be
effective in reducing a three-year event rate of adenomas and second primary colorectal
cancers in patients previously treated for Stages 0 through III colon cancer.
PALO-15-17 is a clinical study assessing efficacy and safety of a single dose of
palonosetron 0.25 mg administered as a 30-minute IV infusion compared to palonosetron 0.25
mg administered as a 30-second IV bolus (Aloxi, an antiemetic drug), both given with oral
dexamethasone. The objective of the study is to demonstrate that infused IV palonosetron
0.25 mg is as effective as (non-inferior to) injected palonosetron IV 0.25 mg to prevent
nausea and vomiting ... Read More
This trial will evaluate two separate groups of patients with stage IIIB/IV non-small cell
lung cancer. The objective of Group 1 is to investigate an FDA-approved drug in stage
IIIB/IV non-small cell lung cancer patients that has spread to the bones. The objective of
Group 2 is to see if a blood test can be used to predict when cancer-related bone lesions
develop. This trial is seeking patients 18 years or older that have been diagnosed with
Stage IIIB or ... Read More
This study evaluates the use of Targretin capsules (bexarotene) in combination with standard
chemotherapy for the treatment of metastatic Non-Small Cell Lung Cancer (NSCLC) in patients
who have not yet received chemotherapy for their lung cancer.
The purpose of this trial is to study the efficacy and safety of the triplet combination of
TLK286, carboplatin and paclitaxel as first-line therapy for patients with advanced
non-small cell lung cancer.